SoftBank Group to Launch AI-Based Cancer Treatment Service in Japan
Introduction
SoftBank Group Corp., a Japanese technology investor, has announced its plan to launch an artificial intelligence-based cancer treatment service in Japan that will suggest appropriate treatment by analyzing genetic information and other healthcare data.
The Joint Venture and Operations
SoftBank Group will establish a joint venture with U.S startup Tempus AI Inc. to launch the service in Japan. The joint venture named “SB Tempus Corp.” will begin operations in August and have an investment of 30 billion yen, equally invested in by SoftBank Group and Tempus AI.
Importance of Tailored Medication
SoftBank Group’s aim behind launching the AI-based cancer treatment service in Japan is to promote tailored medication, which is the need of the hour for cancer treatment. The service will help suggest personalized and precise treatment for cancer patients based on their genetic information and healthcare data.
SoftBank Group CEO on Artificial Superintelligence
During a press conference in Tokyo, Masayoshi Son, the Chairman and CEO of SoftBank Group, said that the time has come for AI to contribute to medical care. He also spoke about the potential of artificial superintelligence, which is predicted to be 10,000 times more intelligent than humans. Son said that he believes AI has the potential to save people from intractable diseases that could not be saved by human wisdom.
Conclusion
The launch of the joint venture between SoftBank Group and Tempus AI is a significant step forward in the field of cancer treatment. With tailored medication, AI can help suggest personalized and precise treatment for cancer patients, leading to higher chances of recovery. As SoftBank Group and Tempus AI look towards the future of AI in healthcare, we can expect more groundbreaking developments that will change the way we approach medical care.
Long-tail keywords: SoftBank Group Corp, cancer treatment, genetic information, artificial intelligence, tailored medication, artificial superintelligence, Tempus AI Inc, joint venture, healthcare data.
Originally Post From https://www.nippon.com/en/news/yjj2024062701098/
Read more about this topic at
AI tool helps predicts patient responses to cancer drugs
Current and Future Applications of AI in Cancer Treatment